A study examining novel gene therapy for the treatment of the bleeding disorder hemophilia B will be presented recently at the 52nd Annual Meeting of the American Society of Hematology. Hemophilia B is an inherited bleeding disease in which patients lack proteins that enable the blood to clot.
“The results of this study show promise that gene therapy may play a role in helping treat incurable disorders, such as hemophilia B,” said J. Evan Sadler, MD, PhD, current ASH President-Elect, and Professor of Medicine at Washington University School of Medicine, St. Louis.
Read more here: http://www.bioresearchonline.com/article.mvc/Study-Examines-Novel-Gene-Therapy-Approach
